Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Recombinant TIL Cell Therapy for Salvage Solid Tumor Patients

Award Number: R43CA232942
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/05/2018
PERIOD OF PERFORMANCE END DATE: 08/31/2020

Group Awards By:

View Award Description

Recombinant TIL Cell Therapy for Salvage Solid Tumor Patients - PROJECT SUMMARY Project Title: Recombinant TIL Cell Therapy for Salvage Solid Tumor Patients Organization: GigaMune Inc. PI: Matthew J Spindler, Ph.D. Expanded T cells isolated from tumor infiltrating lymphocytes (TILs) have achieved remarkable clinical efficacy for the treatment of metastatic melanoma. TILs are composed of a polyclonal mix of tumor-reactive T cell receptors (TCRs), and several pioneering groups have isolated individual therapeutic TCRs targeting public tumor-associated antigens from TILs. The anti-tumor TCRs within the TIL population are able to target the many intracellular and patient-specific neoantigen targets not previously druggable. However, ex vivo expansion of TILs is labor intensive, time consuming, and may result in cellular phenotypic changes that could reduce efficacy. Isolating TCRs from pre-expanded “young” TIL populations would alleviate these issues and could be converted into a recombinant anti-tumor therapy. Leaders in the field have proposed that primary T cells engineered with polyclonal anti-tumor TCRs could be an ideal therapeutic approach. However, conventional T cell discovery relies on low-throughput methods and requires subsequent cloning of individual reactive TCRs. Generating a true “recombinant TIL” therapy requires a technology that can capture millions of T cells per hour and produce polyclonal libraries of TIL TCRs with native TCRa/b pairing. Previously, we developed GigaLink™, a world-leading technology for generating recombinant TCR repertoires from primary T cell samples. We have used this technology to make expression libraries of natively paired TCRs from five clinically-validated malignant melanoma TILs. The Specific Aim of this Phase I SBIR project is to generate pre-clinical efficacy data in mouse models for a recombinant TIL T-cell therapeutic approach for the personalized treatment of cancer. We will achieve the Specific Aim by applying our GigaLink™ technology to patient derived xenograft (PDX) tumor models in mice.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2018	GIGAMUNE, INC.	1 TOWER PL STE 750	SOUTH SAN FRANCISCO	CA	94080	SAN MATEO	USA	Cancer Treatment Research	000	1	1/25/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $300,000 )
2018	2018	GIGAMUNE, INC.	1 TOWER PL STE 750	SOUTH SAN FRANCISCO	CA	94080	SAN MATEO	USA	Cancer Treatment Research	000	1	9/5/2018	NEW	$300,000
														Subtotal = $300,000

Grand Total All Awards = $300,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Recombinant TIL Cell Therapy for Salvage Solid Tumor Patients

Award Number: R43CA232942

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/05/2018

PERIOD OF PERFORMANCE END DATE: 08/31/2020

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer